Entry |
|
Name |
Mutation-activated KRAS/NRAS to PI3K signaling pathway
|
Definition |
(KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD |
Expanded |
(3845v1,4893v1) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572 |
Class |
|
Type |
Variant
|
Pathway |
|
Disease |
H00014 | Non-small cell lung cancer |
|
Gene |
3845 | KRAS; KRAS proto-oncogene, GTPase |
4893 | NRAS; NRAS proto-oncogene, GTPase |
5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
207 | AKT1; AKT serine/threonine kinase 1 |
208 | AKT2; AKT serine/threonine kinase 2 |
10000 | AKT3; AKT serine/threonine kinase 3 |
572 | BAD; BCL2 associated agonist of cell death |
|
Variant |
|
Metabolite |
C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
Reference |
|
Authors |
Schubbert S, Shannon K, Bollag G |
Title |
Hyperactive Ras in developmental disorders and cancer. |
Journal |
|
Reference |
|
Authors |
Adjei AA. |
Title |
Blocking oncogenic Ras signaling for cancer therapy. |
Journal |
|
Reference |
|
Authors |
Janssen KP. |
Title |
Murine models of colorectal cancer: studying the role of oncogenic K-ras. |
Journal |
|
Reference |
|
Authors |
Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L. |
Title |
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. |
Journal |
|
Reference |
|
Authors |
Miller AJ, Mihm MC Jr. |
Title |
Melanoma. |
Journal |
|
LinkDB |
|